1. Home
  2. QURE

as of 02-18-2026 2:19pm EST

$23.86
+$2.11
+9.70%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Founded: 1998 Country:
N/A
Employees: N/A City: AMSTERDAM
Market Cap: 1.9B IPO Year: N/A
Target Price: $56.25 AVG Volume (30 days): 1.9M
Analyst Decision: Buy Number of Analysts: 13
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $7.76 - $71.50 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -42% Revenue Growth (next year): 142.93%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered QURE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 20 hours ago

AI Recommendation

hold
Model Accuracy: 80.50%
80.50%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of uniQure N.V. (QURE)

Gut Robert

Director

Sell
QURE Jan 12, 2026

Avg Cost/Share

$24.84

Shares

25,613

Total Value

$630,483.17

Owned After

40,645

SEC Form 4

Form 1 Form 2
Kaye Jack

Director

Sell
QURE Jan 9, 2026

Avg Cost/Share

$27.28

Shares

6,390

Total Value

$174,319.20

Owned After

20,439

SEC Form 4

Share on Social Networks: